As part of our commitment to enabling member success and sharing best practices from peers, One Nucleus hosted a roundtable bringing together procurement and legal experts. What emerged from these discussions was a clear understanding that procurement can significantly impact your investor story, making it an extremely valuable lever for growth.
The roundtable focused on developing a strategic approach to procurement processes within life science organisations of all types and sizes. The presenters, Mark Hollison of Biotech Procurement Solutions and Rachel Bradley of Penningtons Manches…
by Tony Jones, CEO, One Nucleus
As everyone heads into the summer break with the sun shining and batteries in need of recharging, it is only natural that for many, thoughts turn to what is coming up after the vacation and what is on the wish list to achieve by the end of 2025.
As the first half of the year has demonstrated, from the optimism many entered JPM Week 2025 with at the start of January, described at Genesis 2024. to the challenging impact of the impending world events and political change, the unexpected can happen in the world of biotech. Whilst the funding and deal landscape…
By Monalisa Breazu, Learning & Development Administrator
In the life sciences sector, we talk a lot about innovation, regulation, and breakthroughs, but how often do we stop to think about how well the entire organisation understands the journey from lab bench to market launch?
For those in scientific roles, the stages of drug development are often familiar territory, That said, knowledge gaps can still exist between the Research and Development stages even within the same organisation. In an era of increasingly multi-disciplinary approaches to R&D. team cohesion can be an even…
by Tony Jones, CEO, One Nucleus
If there has been one topic that remains consistently high on the list of things that keep bio-entrepreneurs and their executive team colleagues awake at night, then raising finance and the investment climate is it. Of course, other factors are vital to success also, but the phrase ‘Cash is King’ is a cliché for a reason. This, particularly over an extended period such as the past two years or more when raising capital has been so challenging, compounded by world events, the phrase has never seemed more relevant. The lack of investment flowing across the…
When the goal is growth, building a scalable lab ops tech stack is critical. In a recent webinar, Joel Basken, Director of Operations, and Nicolette Surges, Lab Manager at Enveda Bioscience, a startup based in Colorado, shared invaluable insights and lessons on optimizing lab operations for scalability.
Enveda’s story: A real-life example of a scalable tech stackThe right tech stack for each startup varies, but Enveda has found success with the following solutions:
- Lab supply procurement: ZAGENO- ERP: Netsuite- Project management: Jira- Equipment and asset management: Qualer- Environment…
Bringing a novel therapeutic from concept to candidate is a complex journey, but what if you could streamline that process without compromising quality? In this case study, discover how BioDuro’s integrated drug discovery model helped a biotech partner progress from hit identification to a preclinical candidate in just 16 months.
BioDuro successfully helped a biotech customer advance a kinase inhibitor for inflammatory disease from hit identification to a preclinical candidate (PCC) in just 16 months. The project was executed in three distinct phases — 3 months for Hit…
By Priya Kalia, SciTribe and Miranda Weston-Smith, BioBeat
Making momentum for deals in a changing world was at the heart of BioBeat25 discussions. The meeting, on “Getting ahead of the curve in biotech,” took place at the Cambridge Union on 8 May 2025 with over 100 delegates of entrepreneurs, investors and industry specialists. With outstanding speakers, agility, openness to new strategies, and focus on delivery came through as core themes. The first panel explored current partnership hotspots between small biotech and large pharma, and the second shared practical tips on how to…
The Fisher Scientific channel is proud to have been re-awarded as a Preferred Supplier to its members. Under this renewed and expanded agreement, One Nucleus Gold members can benefit from significant cost savings through the established purchasing framework.
In the first four months of 2025 alone, Fisher Scientific delivered £1.97 million in product savings for Gold members from list pricing, including overall price reductions based on the 2024 hotlist pricing.
New for 2025: Enhanced Support for Sustainable Purchasing
The new 2025 Preferred Supplier agreement goes even further—now offering…
by Tony Jones, CEO, One Nucleus
One Nucleus has been busy developing plans for being in Boston from 15 June 2025, complementing the UK@BIO plans where possible, whilst giving members a chance to maximise their return on investment summarised as follows (see also the BIO page on our website). Sunday 15 June 13.00-17.00 Landing Your Company In The Boston Life Science Ecosystem hosted by Life Science Nation
Life Science Nation (LSN) is offering an exclusive opportunity for RESI Boston June 2025 attendees and other international companies in Boston that week to gain invaluable insights…
by Tony Jones, CEO, One Nucleus
Continuing the series of blogs about the way in which One Nucleus views the nurturing of our community to facilitate the success of our members, the focus this time is on how we can leverage technology to enhance the ‘One Nucleus Bump’ effect.
The Value of Human Collisions
In the first two parts of the series, Nurturing Your Local Ambassadors to Enable Your International Success and Creating the Home of Champions, readers may recall how the themes of your network contacts helping to amplify your visibility and why being part of a trusted community leads to…